A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An NRG Oncology/GOG study

Publication | Open Access

DOI Full Paper Access

Citations

References

2019

Year

Roisin E. O’Cearbhaill, Wei Deng, Lee-may Chen, Joseph A. Lucci, Kian Behbakht, Nick M. Spirtos, Carolyn Y. Muller, Benedict B. Benigno, Matthew A. Powell, Emily Berry,

Gynecologic Oncology

VaccinationPolyvalent Vaccine-klh ConjugatePhase IiMedicineThird Complete RemissionImmunologyVaccine TrialTherapeutic VaccineVaccine EfficacyCancer TreatmentOncologyRadiation OncologyGynecology OncologyOvarian Cancer